-
Acusphere (Watertown, Massachusetts) said last month that it has entered into a collaboration, license and supply agreement with Nycomed (Roskilde, Denmark) for the European development and marketing rights to Acuspheres lead product candidate, AI-700, an ultrasound contrast agent currently in Phase III clinical trials for assessing myocardial perfusion in the diagnosis of coronary heart disease.
-
Escalon Medical (Wayne, Pennsylvania) reported that the board of Drew Scientific Group (London) has recommended that its shareholders accept Escalons revised exchange offer.
-
CompuMed (Los Angeles, California), a medical informatics company serving healthcare with diagnostic software solutions, said that it has been awarded a five-year renewal of its contract to provide electrocardiogram (ECG) interpretation systems and services for the New York State Department of Correctional Services (NYDOCS). NYDOCS will purchase a minimum of 87 new CardioGram systems along with ongoing ECG remote interpretation services.
-
While working in the ED one night, a nurse noticed a strange feeling around her left cheek.
-
Daniel Schultz, MD, acting director of the FDAs Center for Devices and Radiological Health (CDRH) since April, last month had the acting term removed from his title by acting FDA Commissioner Lester Crawford. In announcing the appointment of Schultz to head CDRH, the agencys medical device unit, Crawford said he brings to our medical device program the ideal combination of skills, experience and temperament to ensure that FDAs medical device program is second to none.
-
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine, for the treatment of HIV-1 infections. Each tablet contains 600 mg of abacavir and 300 mg of lamivudine for once daily administration. The combination is marketed by GlaxoSmithKline as Epzicom.
-
The FDA has approved a 5-nitroimidazole for the treatment of trichomoniasis, giardiasis, and amebiasis. Tinidazole, a second-generation nitroimidazole antiprotozoal agent, is marketed as Tindamax by Presutti Laboratories.
-
GEMINI Trial; CAMELOT Trial; INVEST Trial; The Dangers of Vitamin E; FDA Actions.
-
